Samsung Biologics Completes Acquisition of Rockville Plant in U.S., Secures First Overseas Production Base

Total Global Production Capacity Expanded to 845,000 Liters

Samsung Biologics announced on April 1 that it has finalized the acquisition of GlaxoSmithKline (GSK)'s biopharmaceutical manufacturing facility in Rockville, Maryland, USA, on March 31 (local time), thereby securing its first production base in the United States.

Exterior view of the biopharmaceutical manufacturing facility in Rockville, Maryland, USA, acquired by Samsung Biologics. Samsung Biologics

Samsung Biologics completed the acquisition after approximately three months of follow-up procedures since signing the contract in December last year. The acquisition was made through its U.S. subsidiary, Samsung Biologics America.

The Rockville facility is a drug substance (DS) manufacturing plant with a total capacity of 60,000 liters. It consists of two manufacturing buildings. The facility is equipped with infrastructure capable of producing antibody drugs in various quantities, ranging from clinical to commercial scale. It is reported that, through future expansion, the plant could increase its capacity up to 100,000 liters.

With this acquisition, Samsung Biologics has increased its total production capacity from 785,000 liters to 845,000 liters. In particular, by establishing a customer support base in North America, the company has created a dual production system connecting Songdo, Korea, and Rockville, USA, enabling it to provide global clients with stable and flexible manufacturing options.

At the acquisition completion ceremony held on the 31st (local time) at the biopharmaceutical production facility in Rockville, Maryland, USA, John Rim, CEO of Samsung Biologics, is delivering a commemorative speech. Samsung Biologics

Samsung Biologics has ensured operational continuity by retaining all 500 local professional employees. Through the integration process between the two production bases, the company plans to not only secure a stable supply of existing products but also actively expand new contracts. In addition, considering mid- to long-term demand and operational status, the company is also reviewing further investments, including expanding the production capacity and advancing the technology of the Rockville facility.

John Rim, CEO of Samsung Biologics, stated, "This acquisition is a significant step in expanding our global manufacturing network," adding, "We will maintain operational continuity and a stable supply system together with the experienced professionals at the Rockville facility."

This content was produced with the assistance of AI translation services.